Screening strategy for the selection of Leishmania spp epitopes in humans through molecular interactions analysis: A bioinformatics approach
DOI:
https://doi.org/10.62059/LatArXiv.preprints.530Keywords:
leishmaniasis, T epitopes, HLA-DR, molecular docking, bioinformaticsAbstract
Leishmaniasis is a disease that causes a cutaneous lesion where the vector insect bites. In Colombia this disease is a big public health problem. The intracellular parasite invades macrophages parasitophorous vacuole, therefore parasite elimination needs TH1 lymphocyte activation with INFγ production and Nitric Oxide synthesis inside macrophages, so antigen presentation by binding short parasite sequences to MHC class II pocket is critical. Such interactions may be predicted with bioinformatic tools. The aim of this work was to identify linear sequences from immunogenic proteins of Leishmania (Viannia) spp. through bioinformatic tools against MHC class II human molecules. Methodology: linear sequences of GP63, HSP70 y PEPCK were taken from L. panamensis and binding of 15mer peptides to different HLA-DR*04s were predicted. Highly conserved sequences were selected among the parasite species and null or low identity among human proteins. Finally molecular docking was performed against HLA-DR*04:01 pocket. Results: 3 sequences were identified as potential Leishmanial T epitopes. Conclusion: GP63267-282, GP63282-297; and PEPCK535-550 peptides could induce a Th1 response in humans and therefore they can be evaluated as prophylactic or therapeutic candidates against leishmaniasis.
References
1. Leishmaniasis [Internet]. [cited 2025 May 5]. Available from: https://www.who.int/health-topics/leishmaniasis#tab=tab_1
2. Instituto Nacional de Salud. Sistema de Vigilancia SIVIGILA [Internet]. [cited 2022 Jun 16]. Available from: https://www.ins.gov.co/Direcciones/Vigilancia/Paginas/SIVIGILA.aspx
3. Costa-Da-silva AC, Nascimento D de O, Ferreira JRM, Guimarães-Pinto K, Freire-De-lima L, Morrot A, et al. Immune Responses in Leishmaniasis: An Overview. Trop Med Infect Dis [Internet]. 2022 Apr 1 [cited 2023 Dec 3];7(4). Available from: https://pubmed.ncbi.nlm.nih.gov/35448829/
4. Scott P. Long-lived skin-resident memory T cells contribute to concomitant immunity in cutaneous leishmaniasis. Cold Spring Harb Perspect Biol [Internet]. 2020 Oct 1 [cited 2025 May 5];12(10):1–11. Available from: https://pubmed.ncbi.nlm.nih.gov/32839202/
5. Kedzierski L. Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis [Internet]. 2010 [cited 2023 Dec 3];2(2):177. Available from: /pmc/articles/PMC2889658/
6. Liao WWP, Arthur JW. Predicting peptide binding to Major Histocompatibility Complex molecules. Autoimmun Rev [Internet]. 2011 Jun [cited 2025 May 5];10(8):469–73. Available from: https://pubmed.ncbi.nlm.nih.gov/21333759/
7. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res [Internet]. 2004 Mar 1 [cited 2024 Jan 25];32(5):1792–7. Available from: https://dx.doi.org/10.1093/nar/gkh340
8. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021 596:7873 [Internet]. 2021 Jul 15 [cited 2025 May 15];596(7873):583–9. Available from: https://www.nature.com/articles/s41586-021-03819-2
9. Varadi M, Bertoni D, Magana P, Paramval U, Pidruchna I, Radhakrishnan M, et al. AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic Acids Res [Internet]. 2024 Jan 5 [cited 2025 May 15];52(D1):D368–75. Available from: https://dx.doi.org/10.1093/nar/gkad1011
10. PyMOL | pymol.org [Internet]. [cited 2025 May 15]. Available from: https://pymol.org/
11. Reynisson B, Barra C, Kaabinejadian S, Hildebrand WH, Peters B, Peters B, et al. Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data. J Proteome Res. 2020 Jun 5;19(6):2304–15.
12. Racle J, Guillaume P, Schmidt J, Michaux J, Larabi A, Lau K, et al. Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes. Immunity [Internet]. 2023 Jun 13 [cited 2024 Sep 3];56(6):1359-1375.e13. Available from: http://www.cell.com/article/S1074761323001292/fulltext
13. Gonzalez-Galarza FF, McCabe A, Santos EJM Dos, Jones J, Takeshita L, Ortega-Rivera ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res [Internet]. 2020 Jan 1 [cited 2024 Mar 4];48(D1):D783–8. Available from: https://pubmed.ncbi.nlm.nih.gov/31722398/
14. Xu X, Yan C, Zou X. MDockPeP: An ab-initio protein–peptide docking server. J Comput Chem [Internet]. 2018 Oct 30 [cited 2024 Jan 24];39(28):2409–13. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jcc.25555
15. Jamal F, Shivam P, Kumari S, Singh MK, Sardar AH, Pushpanjali, et al. Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis. PLoS One [Internet]. 2017 Aug 1 [cited 2025 May 13];12(8). Available from: https://pubmed.ncbi.nlm.nih.gov/28820895/
16. Mou Z, Li J, Boussoffara T, Kishi H, Hamana H, Ezzati P, et al. Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells. Sci Transl Med [Internet]. 2015 Oct 21 [cited 2025 May 13];7(310). Available from: https://pubmed.ncbi.nlm.nih.gov/26491077/
17. Barazandeh AF, Mou Z, Ikeogu N, Mejia EM, Edechi CA, Zhang WW, et al. The Phosphoenolpyruvate Carboxykinase Is a Key Metabolic Enzyme and Critical Virulence Factor of Leishmania major . The Journal of Immunology [Internet]. 2021 Mar 1 [cited 2025 May 13];206(5):1013–26. Available from: https://pubmed.ncbi.nlm.nih.gov/33462138/
18. Elmahallawy EK, Alkhaldi AAM, Saleh AA. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research. Biomedicine and Pharmacotherapy [Internet]. 2021 Jul 1 [cited 2025 May 13];139. Available from: https://pubmed.ncbi.nlm.nih.gov/33957562/
19. Ikeogu NM, Akaluka GN, Edechi CA, Salako ES, Onyilagha C, Barazandeh AF, et al. Leishmania immunity: Advancing immunotherapy and vaccine development. Microorganisms [Internet]. 2020 Aug 1 [cited 2025 May 13];8(8):1–21. Available from: https://pubmed.ncbi.nlm.nih.gov/32784615/
20. McFarland BJ, Beeson C. Binding interactions between peptides and proteins of the class II Major Histocompatibility Complex. Med Res Rev [Internet]. 2002 [cited 2025 May 13];22(2):168–203. Available from: https://pubmed.ncbi.nlm.nih.gov/11857638/
21. Ferrante A. For many but not for all: How the conformational flexibility of the peptide/MHCII complex shapes epitope selection. Immunol Res [Internet]. 2013 May [cited 2025 May 13];56(1):85–95. Available from: https://pubmed.ncbi.nlm.nih.gov/22753017/
22. Ferreira-Sena EP, Hardoim D de J, Cardoso F de O, d’Escoffier LN, Soares IF, Carvalho JPR da S, et al. A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins of Leishmania amazonensis Specific for Major Histocompatibility Complex Class I. Int J Mol Sci [Internet]. 2023 Mar 1 [cited 2025 May 13];24(6). Available from: https://pubmed.ncbi.nlm.nih.gov/36983046/
23. Saha S, Vashishtha S, Kundu B, Ghosh M. In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani. BMC Bioinformatics [Internet]. 2022 Dec 1 [cited 2025 May 13];23(1). Available from: https://pubmed.ncbi.nlm.nih.gov/35931960/
Downloads
Downloads
Posted
Categories
Data Availability Statement
Los datos no están disponibles en ningún repositorio, sin embargo podrían ser compartidos a cualquier persona que lo solicite.
License
Copyright (c) 2025 Magda Melissa Flórez, Julián David Rodríguez, Francy Elaine Torres (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This preprint contains the reported license and associated copyright. Once published in an associated journal or other publisher, the published version assumes the publisher's terms and conditions.
